Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;14(4):426–432. doi: 10.1111/j.1750-3639.2004.tb00087.x

Amyloid β‐Peptide(1‐42) Contributes to the Oxidative Stress and Neurodegeneration Found in Alzheimer Disease Brain

D Allan Butterfield 1,2,✉, Debra Boyd‐Kimball 1
PMCID: PMC8096022  PMID: 15605990

Abstract

Oxidative stress is extensive in Alzheimer disease (AD) brain. Amyloid β‐peptide (1–42) has been shown to induce oxidative stress and neurotoxicity in vitro and in vivo. Genetic mutations that result in increased production of Aβ1–42 from amyloid precursor protein are associated with an early onset and accelerated pathology of AD. Consequently, Aβ1–42 has been proposed to play a central role in the pathogenesis of AD as a mediator of oxidative stress. In this review, we discuss the role of Aβ1–42 in the lipid peroxidation and protein oxidation evident in AD brain and the implications of such oxidative stress for the function of various proteins that we have identified as specifically oxidized in AD brain compared to control, using proteomics methods. Additionally, we discuss the critical role of methionine 35 in the oxidative stress and neurotoxic properties exhibited by Aβ1–42.

Full Text

The Full Text of this article is available as a PDF (262.6 KB).

REFERENCES

  • 1. Aksenov MY, Aksenova MV, Butterfield DA, Markesbery WR (2000) Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem 74:2520–2527. [DOI] [PubMed] [Google Scholar]
  • 2. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R (2003) Neurotoxic, Redox‐competent Alzheimer's β‐amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278:42959–42965. [DOI] [PubMed] [Google Scholar]
  • 3. Blass JP, Gibson GE (1991) The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol 147:513–525. [PubMed] [Google Scholar]
  • 4. Butterfield DA Bush AI (2004) Alzheimer's amyloid β‐peptide 1–42: involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25:563–568. [DOI] [PubMed] [Google Scholar]
  • 5. Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta‐peptide‐associated free radical oxidative stress. Free Rad Biol Med 32:1050–1060. [DOI] [PubMed] [Google Scholar]
  • 6. Butterfield DA, Stadtman ER (1997) Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2:161–191. [Google Scholar]
  • 7. Butterfield DA, Boyd‐Kimball D, Castegna A (2003) Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86:1313–1327. [DOI] [PubMed] [Google Scholar]
  • 8. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta‐peptide. Trends Mol Med 7:548–554. [DOI] [PubMed] [Google Scholar]
  • 9. Butterfield DA (2002) Amyloid beta‐peptide 1–42‐induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36:1307–1313. [DOI] [PubMed] [Google Scholar]
  • 10. Butterfield DA (2003) Amyloid beta‐peptide 1–42‐associated free radical‐induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr Med Chem 10:2651–2659. [DOI] [PubMed] [Google Scholar]
  • 11. Butterfield DA (2004) Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 1000:1–7. [DOI] [PubMed] [Google Scholar]
  • 12. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Marksbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain part I: creatine kinase BB, glutamine synthetase, and ubiquitin carboxy‐terminal hydrolase L‐1. Free Rad Biol Med 33:562–571. [DOI] [PubMed] [Google Scholar]
  • 13. Castegna A, Aksnov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomics identification of oxidatively modified proteins in Alzheimer's disease brain part II: dihydropyrimidinase related protein II, a‐enolase, and heat schock cognate 71. J Neurochem 82:1524–1532. [DOI] [PubMed] [Google Scholar]
  • 14. Castegna A, Lauderback CM, Mohmmad‐Abdul H, Butterfield DA (2004) Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4‐hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res 1004:193–197. [DOI] [PubMed] [Google Scholar]
  • 15. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85:1394–1401. [DOI] [PubMed] [Google Scholar]
  • 16. Coleman PD, Flood DG (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 8:521–545. [DOI] [PubMed] [Google Scholar]
  • 17. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR (2003) Metal binding and oxidation of Amyloid‐β within isolated senile plaque cores: raman microscopic evidence. Biochemistry 42:2768–2773. [DOI] [PubMed] [Google Scholar]
  • 18. Drake J, Link CD, Butterfield DA (2003) Oxidative Stress precedes fibrillar deposition of Alzheimer's disease amyloid β‐peptide 1–42 in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24:415–420. [DOI] [PubMed] [Google Scholar]
  • 19. Drake J, Petroze R, Castegna A, Ding Q, Keller JN, Markesbery WR, Lovell MA, Butterfield DA (2004) 4‐Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci Letts 356:155–158. [DOI] [PubMed] [Google Scholar]
  • 20. Drake J, Sultana R, Aksenova M, Calabrese V, Butterfield DA (2003) Elevation of mitochondrial glutathione by gamma‐glutamylcysteine ethyl ester protects mitochondria against peroxynitrite‐induced oxidative stress. J Neurosci Res 74:917–927. [DOI] [PubMed] [Google Scholar]
  • 21. Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA (2002) Elevation of brain glutathione by g‐glutamylcysteine ethyl ester protects against peroxynitrite‐induced oxidative stress. J Neurosci Res 68:776–784. [DOI] [PubMed] [Google Scholar]
  • 22. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4‐hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81–128. [DOI] [PubMed] [Google Scholar]
  • 23. Giacobini E (2003) Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 18:S1–S5. [DOI] [PubMed] [Google Scholar]
  • 24. Good PF, Werner P, Hsu A, Olanow C, Perl DP (1996) Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149:21–27. [PMC free article] [PubMed] [Google Scholar]
  • 25. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita P, Wu JF, Carney JM, Lovell M, Markebery WR, Butterfield DA (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146–2156. [DOI] [PubMed] [Google Scholar]
  • 26. Hou L, Kang I, Marchant RE, Zagorski MG (2002) Methionine 35 oxidation reduces fibril assembly of the amyloid abeta‐1–42 peptide of Alzheimer's disease. J Biol Chem 277:40173–40176. [DOI] [PubMed] [Google Scholar]
  • 27. Kanski J, Aksenova M, Butterfield DA (2002) Substitution of isoleucine‐31 by helical‐breaking proline abolishes oxidative and neurotoxic properties of Alzheimer's amyloid beta‐peptide. Free Radic Biol Med 32:1205–1211. [DOI] [PubMed] [Google Scholar]
  • 28. Katzman R, Saitoh T (1991) Advances in Alzheimer's disease. FASEB J 5:278–86. [PubMed] [Google Scholar]
  • 29. Keller JN, Hanni KB, Markesbery WM (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75:436–439. [DOI] [PubMed] [Google Scholar]
  • 30. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, Butterfield, DA (1999) Peroxynitrite‐induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's Disease. J Neurochem 72:310–317. [DOI] [PubMed] [Google Scholar]
  • 31. Kou YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler‐Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid‐β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276:12991–12998. [DOI] [PubMed] [Google Scholar]
  • 32. Lauderback CM, Hackett JM, Huang F, Keller JN, Szweda L, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT‐1, is oxidatively modified by 4‐hydroxy‐2‐nonenal in the Alzheimer's disease brain: the role of Aβ1–42 . J Neurochem 78:413–416. [DOI] [PubMed] [Google Scholar]
  • 33. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22:187–194. [DOI] [PubMed] [Google Scholar]
  • 34. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M (1999) Expression of the dihydropyrimidinase related protein 2 (DRP‐2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl 57:161–177. [DOI] [PubMed] [Google Scholar]
  • 35. Mark RJ, Lovell MA, Markesberry WR, Uchida K Mattson MP (1997) A role for 4‐hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β‐peptide. J Neurochem 68:255–264. [DOI] [PubMed] [Google Scholar]
  • 36. Markesbery MR (1997) Oxidative Stress Hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134–147. [DOI] [PubMed] [Google Scholar]
  • 37. Markesbery WR, Lovell MA (1998) Four‐hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33–36. [DOI] [PubMed] [Google Scholar]
  • 38. Masliah E, Alford M, De Teresa R, Mallory M, Hansen L (1995) Deficient glutamate transport is associtated with neurodegeneration in Alzheimer's disease. Ann Neurol 40:759–766. [DOI] [PubMed] [Google Scholar]
  • 39. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, Terenius L (1994) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Nat Acad Sci U S A 91:8378–8382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Ojika K, Tsugu Y, Mitake S, Otsuka Y, Takada E (1998) NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Neuroscience 101:341–352. [DOI] [PubMed] [Google Scholar]
  • 41. Pocernich CB, and Butterfield DA (2003) Acrolien inhibits NADH‐linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res 5:515–520. [DOI] [PubMed] [Google Scholar]
  • 42. Pogocki D, and Schöneich C (2002) Redox properties of Met35 in neurotoxic b‐amyloid peptide. A molecular modeling study. Chem Res Toxicol 15:408–418. [DOI] [PubMed] [Google Scholar]
  • 43. Riek R, Güntert P, Döbeli H, Wipf B, Wüthrich K (2001) NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque‐competence, Aβ(1–40)ox and Aβ1–42 ox . Eur J Biochem 268:5930–5936. [DOI] [PubMed] [Google Scholar]
  • 44. Rosser MN, Svendsen C, Hunt SP, Mountjoy CQ, Roth M, Iversen LL (1982) The substantia innominata in Alzheimer's disease: a histochemical and biochemical study of cholinergic marker enzymers. Neurosci Lett 28:217–222. [DOI] [PubMed] [Google Scholar]
  • 45. Scheltens P, Korf ESC (2000) Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. Curr Opin Neuro 13:391–396. [DOI] [PubMed] [Google Scholar]
  • 46. Schonberger SJ, Edgar PF, Kydd R, Faull RLM, Cooper GJS (2001) Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. Proteomics 1:1519–1528. [DOI] [PubMed] [Google Scholar]
  • 47. Schöneich C, Pogocki D, Hug GL, Bobrowski K (2003) Free radical reactions of methionine in peptides: mechanisms relevant to beta‐amyloid oxidation and Alzheimer's disease. J Am Chem Soc 125:13700–13713. [DOI] [PubMed] [Google Scholar]
  • 48. Seilheimer B, Bohrmann B, Bondolfi L, Müller F, Stüber D, Dübeli H (1997) The toxicity of the Alzheimer's β‐amyloid peptide correlated with a distinct fiber morphology. J Struct Biol 119:59–71. [DOI] [PubMed] [Google Scholar]
  • 49. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta‐protein. J Alzheimers Dis 3:75–80. [DOI] [PubMed] [Google Scholar]
  • 50. Shringarpure R, Grune T, Davies KJ (2001) Protein oxidation and 20S proteasome‐dependent proteolysis in mammalian cells. Cell Mol Life Sci 58:1442–1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite‐mediated damage in Alzheimer's disease. J Neurosci 17:2653–2657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55:342–345. [DOI] [PubMed] [Google Scholar]
  • 53. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, Butterfield DA (1997) The lipid peroxidation product, 4‐hydroxy‐2‐trans‐nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem 69:1161–1169. [DOI] [PubMed] [Google Scholar]
  • 54. Sultana R, Newman S, Mohammad‐Abdul H, Butterfield DA (2004) Protective effect of the xanthate, D609, on Alzheimer's amyloid β‐peptide 1–42‐induced oxidative stress in primary neuronal cells. Free Rad Res 38:449–458. [DOI] [PubMed] [Google Scholar]
  • 55. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999) Alterations of 3‐nityrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Letts 269:52–54. [DOI] [PubMed] [Google Scholar]
  • 56. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S (2002) Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 27:1245–1253. [DOI] [PubMed] [Google Scholar]
  • 57. Uchida K (2003) 4‐Hydroxynonenal: a product and mediator of oxidative stress. Prog Lipid Res 42:318–343. [DOI] [PubMed] [Google Scholar]
  • 58. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ1–42 and Aβ(25–35). J Am Chem Soc 123:5625–5631. [DOI] [PubMed] [Google Scholar]
  • 59. Varadarajan S, Yatin S, Aksenova M, Butterfield DA (2000) Review: Alzheimer's Amyloid β‐peptide‐associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184–208. [DOI] [PubMed] [Google Scholar]
  • 60. Yatin SM, Aksenov M, Butterfield DA (1999) The antioxidant vitamin E modulated amyloid β‐peptide‐induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 24:427–435. [DOI] [PubMed] [Google Scholar]
  • 61. Yatin SM, Varadarajan S, Butterfield DA (2000) Vitamin E prevents Alzheimer's amyloid β‐peptide 1–42‐induced neuronal protein oxidation and reactive oxygen species Production. J Alzheimer's Dis 2:123–131. [DOI] [PubMed] [Google Scholar]
  • 62. Yatin SM, Varadarajan S, Link CD, Butterfield DA (1999) In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β‐peptide 1–42 . Neurobiol Aging 20:325–330. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES